Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome.

Wang H, Lekbaby B, Fares N, Augustin J, Attout T, Schnuriger A, Cassard AM, Panasyuk G, Perlemuter G, Bieche I, Vacher S, Selves J, Péron JM, Bancel B, Merle P, Kremsdorf D, Hall J, Chemin I, Soussan P.

Hepatol Int. 2019 Jul;13(4):454-467. doi: 10.1007/s12072-019-09950-7. Epub 2019 May 28.

PMID:
31140152
2.

[Prevention of liver fibrosis and liver cancer linked to hepatitis B virus in Africa: the Prolifica study].

Cohen D, Shimakawa Y, Ndow G, Sow A, Tamba S, Njie R, Lo G, Ghosh S, Toure-Kane C, Ka M, Mboup S, Okeke E, Toure S, Diop M, D'Alessandro U, Taylor-Robinson S, Mendy M, Zoulim F, Thursz MR, Lemoine M, Chemin I.

Med Sci (Paris). 2019 May;35(5):431-439. doi: 10.1051/medsci/2019076. Epub 2019 May 22. French.

3.

Hepatitis B core-related antigen (HBcrAg): an alternative to HBV DNA to assess treatment eligibility in Africa.

Shimakawa Y, Ndow G, Njie R, Njai HF, Takahashi K, Akbar SMF, Cohen D, Nayagam S, Jeng A, Ceesay A, Sanneh B, Baldeh I, Imaizumi M, Moriyama K, Aoyagi K, D'Alessandro U, Mishiro S, Chemin I, Mendy M, Thursz MR, Lemoine M.

Clin Infect Dis. 2019 May 17. pii: ciz412. doi: 10.1093/cid/ciz412. [Epub ahead of print]

PMID:
31102406
4.

Toll-like receptor 9 polymorphisms and Hepatitis B virus clearance in Moroccan chronic carriers.

Chihab H, Zaidane I, Elhabazi A, Jadid FZ, El Fihri R, Elmessaoudi-Idrissi M, Chair M, Badre W, Tahiri M, Pineau P, Chemin I, Ezzikouri S, Benjelloun S.

Gene. 2019 Mar 1;687:212-218. doi: 10.1016/j.gene.2018.11.041. Epub 2018 Nov 16.

PMID:
30453064
5.

Hepatitis B Virus Blocks the CRE/CREB Complex and Prevents TLR9 Transcription and Function in Human B Cells.

Tout I, Gomes M, Ainouze M, Marotel M, Pecoul T, Durantel D, Vaccarella S, Dubois B, Loustaud-Ratti V, Walzer T, Alain S, Chemin I, Hasan U.

J Immunol. 2018 Oct 15;201(8):2331-2344. doi: 10.4049/jimmunol.1701726. Epub 2018 Sep 5.

PMID:
30185518
6.

Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa.

Shimakawa Y, Njie R, Ndow G, Vray M, Mbaye PS, Bonnard P, Sombié R, Nana J, Leroy V, Bottero J, Ingiliz P, Post G, Sanneh B, Baldeh I, Suso P, Ceesay A, Jeng A, Njai HF, Nayagam S, D'Alessandro U, Chemin I, Mendy M, Thursz M, Lemoine M.

J Hepatol. 2018 Oct;69(4):776-784. doi: 10.1016/j.jhep.2018.05.024. Epub 2018 Jul 1.

7.

Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.

Virlogeux V, Berthillon P, Bordes I, Larrat S, Crouy S, Scholtès C, Pradat P, Maynard M, Zoulim F, Leroy V, Chemin I, Trépo C, Petit MA.

Clin Res Hepatol Gastroenterol. 2018 Sep;42(4):313-318. doi: 10.1016/j.clinre.2018.02.002. Epub 2018 Mar 16.

PMID:
29551607
8.

Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes.

Guillot C, Martel N, Berby F, Bordes I, Hantz O, Blanchet M, Sureau C, Vaillant A, Chemin I.

PLoS One. 2017 Jun 21;12(6):e0179697. doi: 10.1371/journal.pone.0179697. eCollection 2017.

9.

Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes.

Lempp FA, Wiedtke E, Qu B, Roques P, Chemin I, Vondran FWR, Le Grand R, Grimm D, Urban S.

Hepatology. 2017 Sep;66(3):703-716. doi: 10.1002/hep.29112. Epub 2017 Jul 18.

PMID:
28195359
10.

Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries.

Ghosh S, Sow A, Guillot C, Jeng A, Ndow G, Njie R, Toure S, Diop M, Mboup S, Kane CT, Lemoine M, Thursz M, Zoulim F, Mendy M, Chemin I.

J Viral Hepat. 2016 Nov;23(11):897-904. doi: 10.1111/jvh.12561. Epub 2016 Jun 29.

PMID:
27353593
11.

Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study.

Lemoine M, Shimakawa Y, Njie R, Taal M, Ndow G, Chemin I, Ghosh S, Njai HF, Jeng A, Sow A, Toure-Kane C, Mboup S, Suso P, Tamba S, Jatta A, Sarr L, Kambi A, Stanger W, Nayagam S, Howell J, Mpabanzi L, Nyan O, Corrah T, Whittle H, Taylor-Robinson SD, D'Alessandro U, Mendy M, Thursz MR; PROLIFICA investigators.

Lancet Glob Health. 2016 Aug;4(8):e559-67. doi: 10.1016/S2214-109X(16)30130-9.

12.

Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases.

Petit MA, Berthillon P, Pradat P, Arnaud C, Bordes I, Virlogeux V, Maynard M, Bailly F, Zoulim F, Chemin I, Trépo C.

Clin Res Hepatol Gastroenterol. 2015 Dec;39(6):699-704. doi: 10.1016/j.clinre.2015.03.002. Epub 2015 Apr 18.

PMID:
25900002
13.

PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.

Guillot C, Favaudon V, Herceg Z, Sagne C, Sauvaigo S, Merle P, Hall J, Chemin I.

BMC Cancer. 2014 Aug 20;14:603. doi: 10.1186/1471-2407-14-603.

14.

Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma.

Kitab B, Ezzikouri S, Alaoui R, Nadir S, Badre W, Trepo C, Chemin I, Benjelloun S.

Liver Int. 2014 Jul;34(6):e144-50. doi: 10.1111/liv.12482. Epub 2014 Mar 11.

PMID:
24502524
15.

Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD Expert Meeting.

Robert PH, Konig A, Andrieu S, Bremond F, Chemin I, Chung PC, Dartigues JF, Dubois B, Feutren G, Guillemaud R, Kenisberg PA, Nave S, Vellas B, Verhey F, Yesavage J, Mallea P.

J Nutr Health Aging. 2013;17(8):653-60. doi: 10.1007/s12603-013-0046-3.

PMID:
24097018
16.

Update on hepatocellular carcinoma breakthroughs: poly(ADP-ribose) polymerase inhibitors as a promising therapeutic strategy.

Guillot C, Hall J, Herceg Z, Merle P, Chemin I.

Clin Res Hepatol Gastroenterol. 2014 Apr;38(2):137-42. doi: 10.1016/j.clinre.2013.07.006. Epub 2013 Aug 13. Review.

PMID:
23953496
17.

Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.

Arnaud C, Pradat P, Spaziante M, Berthillon P, Maynard M, Taliani G, Chemin I, Trépo C, Petit MA.

Antivir Ther. 2013;18(8):1027-32. doi: 10.3851/IMP2671. Epub 2013 Aug 15.

PMID:
23948510
18.

Improved rolling circle amplification (RCA) of hepatitis B virus (HBV) relaxed-circular serum DNA (RC-DNA).

Martel N, Gomes SA, Chemin I, Trépo C, Kay A.

J Virol Methods. 2013 Nov;193(2):653-9. doi: 10.1016/j.jviromet.2013.07.045. Epub 2013 Aug 5.

PMID:
23928222
19.

Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island.

Dupinay T, Gheit T, Roques P, Cova L, Chevallier-Queyron P, Tasahsu SI, Le Grand R, Simon F, Cordier G, Wakrim L, Benjelloun S, Trépo C, Chemin I.

Hepatology. 2013 Nov;58(5):1610-20. doi: 10.1002/hep.26428. Epub 2013 Sep 17.

PMID:
23536484
20.

Distribution of total DNA and cccDNA in serum and PBMCs may reflect the HBV immune status in HBsAg+ and HBsAg- patients coinfected or not with HIV or HCV.

Loustaud-Ratti V, Wagner A, Carrier P, Marczuk V, Chemin I, Lunel F, Fouchard-Hubert I, Ahmed SS, Abergel A, Rousseau A, Lefebvre A, Debette-Gratien M, Denis F, Alain S.

Clin Res Hepatol Gastroenterol. 2013 Sep;37(4):373-83. doi: 10.1016/j.clinre.2012.11.002. Epub 2013 Mar 9.

PMID:
23477988
21.

Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progression.

Kitab B, Essaid El Feydi A, Afifi R, Trepo C, Benazzouz M, Essamri W, Zoulim F, Chemin I, Alj HS, Ezzikouri S, Benjelloun S.

PLoS One. 2012;7(8):e42891. doi: 10.1371/journal.pone.0042891. Epub 2012 Aug 14.

22.

TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia.

Gouas DA, Villar S, Ortiz-Cuaran S, Legros P, Ferro G, Kirk GD, Lesi OA, Mendy M, Bah E, Friesen MD, Groopman J, Chemin I, Hainaut P.

Carcinogenesis. 2012 Jun;33(6):1219-24. doi: 10.1093/carcin/bgs068.

23.

Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma.

Kaur P, Mani S, Cros MP, Scoazec JY, Chemin I, Hainaut P, Herceg Z.

Tumour Biol. 2012 Apr;33(2):325-36. doi: 10.1007/s13277-012-0331-5. Epub 2012 Feb 15.

PMID:
22351518
24.

Unusual presentation of hepatitis B serological markers in an Amerindian community of Venezuela with a majority of occult cases.

Cardona NE, Loureiro CL, Garzaro DJ, Duarte MC, García DM, Pacheco MC, Chemin I, Pujol FH.

Virol J. 2011 Dec 9;8:527. doi: 10.1186/1743-422X-8-527.

25.

Hepatitis B and Hepatitis C Infection Biomarkers and TP53 Mutations in Hepatocellular Carcinomas from Colombia.

Navas MC, Suarez I, Carreño A, Uribe D, Rios WA, Cortes-Mancera F, Martel G, Vieco B, Lozano D, Jimenez C, Gouas D, Osorio G, Hoyos S, Restrepo JC, Correa G, Jaramillo S, Lopez R, Bravo LE, Arbelaez MP, Scoazec JY, Abedi-Ardekani B, Santella RM, Chemin I, Hainaut P.

Hepat Res Treat. 2011;2011:582945. doi: 10.1155/2011/582945. Epub 2011 Oct 31.

26.

The molecular pathology and clinical impact of HBV genetic variability.

Chemin I, Norder H, Soussan P, Chakravarty R.

Hepat Res Treat. 2011;2011:242106. doi: 10.1155/2011/242106. Epub 2011 Nov 9. No abstract available.

27.

Interactions between hepatitis B virus and aflatoxin B(1): effects on p53 induction in HepaRG cells.

Lereau M, Gouas D, Villar S, Besaratinia A, Hautefeuille A, Berthillon P, Martel-Planche G, Nogueira da Costa A, Ortiz-Cuaran S, Hantz O, Pfeifer GP, Hainaut P, Chemin I.

J Gen Virol. 2012 Mar;93(Pt 3):640-50. doi: 10.1099/vir.0.032482-0. Epub 2011 Nov 23.

PMID:
22113009
28.

Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells.

Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trépo C, Hasan U, Chemin I.

PLoS One. 2011;6(10):e26315. doi: 10.1371/journal.pone.0026315. Epub 2011 Oct 25.

29.

Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand.

Galy O, Chemin I, Le Roux E, Villar S, Le Calvez-Kelm F, Lereau M, Gouas D, Vieco B, Suarez I, Navas MC, Chevallier M, Norder H, Srivatanakul P, Karalak A, Sangrajrang S, Trépo C, Hainaut P.

Hepat Res Treat. 2011;2011:697162. doi: 10.1155/2011/697162. Epub 2011 Jun 30.

30.

Evolution of Hepatitis B and C serum markers: a still challenging issue.

Chemin I, Trépo C.

Liver Int. 2011 Aug;31(7):905-7. doi: 10.1111/j.1478-3231.2011.02479.x. Epub 2011 Mar 16. No abstract available.

PMID:
21733079
31.

Hepatitis B genotypes/subgenotypes and MHR variants among Moroccan chronic carriers.

Kitab B, El Feydi AE, Afifi R, Derdabi O, Cherradi Y, Benazzouz M, Rebbani K, Brahim I, Salih Alj H, Zoulim F, Trepo C, Chemin I, Ezzikouri S, Benjelloun S.

J Infect. 2011 Jul;63(1):66-75. doi: 10.1016/j.jinf.2011.05.007. Epub 2011 May 17.

PMID:
21640384
32.

Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake.

Lambert MP, Paliwal A, Vaissière T, Chemin I, Zoulim F, Tommasino M, Hainaut P, Sylla B, Scoazec JY, Tost J, Herceg Z.

J Hepatol. 2011 Apr;54(4):705-15. doi: 10.1016/j.jhep.2010.07.027. Epub 2010 Sep 25.

PMID:
21146512
33.

DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection.

Kaur P, Paliwal A, Durantel D, Hainaut P, Scoazec JY, Zoulim F, Chemin I, Herceg Z.

J Infect Dis. 2010 Sep 1;202(5):700-4. doi: 10.1086/655398.

PMID:
20653444
34.

High prevalence of hepatitis B virus genotype E in Northern Madagascar indicates a West-African lineage.

Dupinay T, Restorp K, Leutscher P, Rousset D, Chemin I, Migliani R, Magnius L, Norder H.

J Med Virol. 2010 Sep;82(9):1515-26. doi: 10.1002/jmv.21865.

PMID:
20648605
35.

Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.

Gouas DA, Shi H, Hautefeuille AH, Ortiz-Cuaran SL, Legros PC, Szymanska KJ, Galy O, Egevad LA, Abedi-Ardekani B, Wiman KG, Hantz O, Caron de Fromentel C, Chemin IA, Hainaut PL.

Carcinogenesis. 2010 Aug;31(8):1475-82. doi: 10.1093/carcin/bgq118. Epub 2010 Jun 10.

PMID:
20538734
36.

Hepatitis B virus replication in primary macaque hepatocytes: crossing the species barrier toward a new small primate model.

Lucifora J, Vincent IE, Berthillon P, Dupinay T, Michelet M, Protzer U, Zoulim F, Durantel D, Trepo C, Chemin I.

Hepatology. 2010 Jun;51(6):1954-60. doi: 10.1002/hep.23602.

PMID:
20301206
37.
38.

Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma.

Pujol FH, Navas MC, Hainaut P, Chemin I.

Cancer Lett. 2009 Dec 1;286(1):80-8. doi: 10.1016/j.canlet.2009.07.013. Epub 2009 Aug 14. Review.

PMID:
19683385
39.

Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection.

Chemin I, Guillaud O, Queyron PC, Trépo C.

J Hepatol. 2009 Oct;51(4):824-5. doi: 10.1016/j.jhep.2009.06.007. Epub 2009 Jun 25. No abstract available.

40.

Editorial foreword special issue "hepatocellular carcinoma--a worldwide translational approach".

Plymoth A, Chemin I, Boffetta P, Hainaut P.

Cancer Lett. 2009 Dec 1;286(1):3-4. doi: 10.1016/j.canlet.2009.03.002. Epub 2009 Apr 7. No abstract available.

PMID:
19356844
41.

Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.

Vincent IE, Lucifora J, Durantel D, Hantz O, Chemin I, Zoulim F, Trepo C.

Antivir Ther. 2009;14(1):131-5.

PMID:
19320247
42.

Hepatitis B virus induced hepatocellular carcinoma.

Chemin I, Zoulim F.

Cancer Lett. 2009 Dec 1;286(1):52-9. doi: 10.1016/j.canlet.2008.12.003. Epub 2009 Jan 14. Review.

PMID:
19147276
43.

Occult B infection in the Brazilian northeastern region: a preliminary report.

Almeida D, Tavares-Neto J, Trepo C, Almeida A, Mello C, Chemin I, Paraná R.

Braz J Infect Dis. 2008 Aug;12(4):310-2.

PMID:
19030731
44.

Immunohistochemical detection of HCV proteins in liver tissue.

Galy O, Vincent I, Chevallier P, Lyandrat N, Chemin I.

Methods Mol Biol. 2009;510:25-30. doi: 10.1007/978-1-59745-394-3_3.

PMID:
19009251
45.

Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA.

Margeridon S, Carrouée-Durantel S, Chemin I, Barraud L, Zoulim F, Trépo C, Kay A.

Antimicrob Agents Chemother. 2008 Sep;52(9):3068-73. doi: 10.1128/AAC.01318-07. Epub 2008 Jul 7.

46.

Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma.

Bengochea A, de Souza MM, Lefrançois L, Le Roux E, Galy O, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P, Scoazec JY, Vitvitski L, Merle P.

Br J Cancer. 2008 Jul 8;99(1):143-50. doi: 10.1038/sj.bjc.6604422. Epub 2008 Jun 24.

47.

Genotype determination in Moroccan hepatitis B chronic carriers.

Ezzikouri S, Chemin I, Chafik A, Wakrim L, Nourlil J, Malki AE, Marchio A, Dejean A, Hassar M, Trepo C, Pineau P, Benjelloun S.

Infect Genet Evol. 2008 May;8(3):306-12. doi: 10.1016/j.meegid.2008.01.010. Epub 2008 Feb 3.

PMID:
18372221
48.

Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C.

Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, Trabaud MA, Chevallier P, Chevallier M, Zoulim F, Trépo C.

J Med Virol. 2007 Aug;79(8):1075-81.

PMID:
17596829
49.

Efficient hepatitis C antigen immunohistological staining in sections of normal, cirrhotic and tumoral liver using a new monoclonal antibody directed against serum-derived HCV E2 glycoproteins.

Galy O, Petit MA, Benjelloun S, Chevallier P, Chevallier M, Srivatanakul P, Karalak A, Carreira C, Lyandrat N, Essaid A, Trepo C, Hainaut P, Chemin I.

Cancer Lett. 2007 Apr 8;248(1):81-8. Epub 2006 Aug 1.

PMID:
16879909
50.

Virtual action planning in Parkinson's disease: a control study.

Klinger E, Chemin I, Lebreton S, Marié RM.

Cyberpsychol Behav. 2006 Jun;9(3):342-7.

PMID:
16780402

Supplemental Content

Loading ...
Support Center